Epigenica AB signs Japan distribution deal to accelerate epigenetic biomarker research
Epigenica AB, the Swedish biotechnology company specialising in epigenetic analysis tools, has entered into a distribution agreement with PrimeTech Co., Ltd., expanding access to its EpiFinder™ platform across the Japanese life science market.
A strategic move into a high-value research market
Japan is widely regarded as one of the world’s foremost life science ecosystems, with substantial investment in genomics, biomarker discovery, and translational research. Under the terms of the agreement, PrimeTech – an established distributor of advanced life science technologies to academic institutions, biotechnology companies, and pharmaceutical organisations across Japan – will distribute Epigenica’s EpiFinder kits and provide local technical support to researchers.
“Japan is a highly innovative market with world leading research institutions and strong interest in advanced omics technologies,” said Mohamad Takwa, CEO and co-founder of Epigenica. “We are delighted to partner with PrimeTech to make EpiFinder more accessible to researchers in Japan and support new discoveries in areas such as cancer biology, aging research, and precision medicine.”
What EpiFinder brings to the laboratory
The EpiFinder platform is designed for high-throughput epigenetic profiling across multiple cell types and tissues. Notably, it also enables detection of epigenetic signals in blood via circulating nucleosomes – an increasingly significant capability in the development of liquid biopsy approaches and non-invasive biomarker discovery. The platform affords researchers a scalable means of studying gene regulation at an epigenomic level.
Expanding international reach
Ryosuke Ogihara, CEO of PrimeTech, commented: “The ability to generate epigenetic information at the scale that EpiFinder offers opens exciting opportunities for biomarker discovery and translational research.”
The agreement forms part of Epigenica’s broader international commercialisation strategy, targeting key research markets where demand for high-resolution epigenomic tools is growing.
